Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
- 1.6k Downloads
Endocrine therapy continues to be the optimal systemic treatment for metastatic ER+HER2− breast cancer. The CDK4/6 inhibitor palbociclib combined with letrozole has recently been shown to significantly improve progression-free survival. Here we examined the cost-effectiveness of this regimen for the Swiss healthcare system. A Markov cohort simulation based on the PALOMA-1 trial (Finn et al. in Lancet Oncol 16:25–35, 2015) was used as the clinical course. Input parameters were based on summary trial data. Costs were assessed from the Swiss healthcare system perspective. Adding palbociclib to letrozole (PALLET) compared to letrozole monotherapy was estimated to cost an additional CHF342,440 and gain 1.14 quality-adjusted life years, resulting in an incremental cost-effectiveness ratio (ICER) of CHF301,227/QALY gained. In univariate sensitivity analyses, no tested variation in key parameters resulted in an ICER below a willingness-to-pay threshold of CHF100,000/QALY. PALLET had a 0 % probability of being cost-effective in probabilistic sensitivity analyses. Lowering PALLET’s price by 75 % resulted in an ICER of CHF73,995/QALY and a 73 % probability of being cost-effective. At current prices, PALLET would cost the Swiss healthcare system an additional CHF155 million/year. Palbociclib plus letrozole cannot be considered cost-effective for the first-line treatment of patients with metastatic breast cancer in the Swiss healthcare system.
KeywordsCost-effectiveness analysis Letrozole Palbociclib Metastatic breast cancer
We thank the SAKK Coordinating Centre and Nextgenediting for reviewing our manuscript.
The Swiss State Secretariat for Education, Research and Innovation (SERI) supported this work.
Compliance with ethical standards
Conflict of interest
All authors declared no potential conflicts of interest related to palbociclib or other drugs mentioned in this article.
- 2.Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, Andrade S, Batel-Marques F (2015) The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer—a systematic review. Breast Cancer Res 17:140. doi: 10.1186/s13058-015-0648-2 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordstrom EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van’t Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) dagger. Ann Oncol 25(10):1871–1888. doi: 10.1093/annonc/mdu385 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE (2014) Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32(29):3307–3329. doi: 10.1200/JCO.2014.56.7479 CrossRefPubMedGoogle Scholar
- 5.Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35. doi: 10.1016/S1470-2045(14)71159-3 CrossRefPubMedGoogle Scholar
- 6.Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P (2015) FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 21(21):4760–4766. doi: 10.1158/1078-0432.CCR-15-1185 CrossRefPubMedGoogle Scholar
- 10.Diebold J, Aebi S (2014) Prognostische und prädiktive Marker beim Mammakarzinom. SZO 1:10–14Google Scholar
- 15.Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, Szucs TD (2009) Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 45:1397–1406. doi: 10.1016/j.ejca.2008.12.01610.1016/j.ejca.2008.12.016 CrossRefPubMedGoogle Scholar
- 16.Joerger M, Matter-Walstra K, Fruh M, Kuhnel U, Szucs T, Pestalozzi B, Schwenkglenks M (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 22(3):567–574. doi: 10.1093/annonc/mdq431 CrossRefPubMedGoogle Scholar
- 18.Matter-Walstra K, Joerger M, Kuhnel U, Szucs T, Pestalozzi B, Schwenkglenks M (2012) Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health 15(1):65–71. doi: 10.1016/j.jval.2011.08.1737 CrossRefPubMedGoogle Scholar
- 25.Lakdawalla DN, Chou JW, Linthicum MT, MacEwan JP, Zhang J, Goldman DP (2015) Evaluating expected costs and benefits of granting access to new treatments on the basis of progression-free survival in non-small-cell lung cancer. JAMA Oncol 1(2):196–202. doi: 10.1001/jamaoncol.2015.0203 CrossRefPubMedGoogle Scholar